JP7795206B2 - 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用 - Google Patents

条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Info

Publication number
JP7795206B2
JP7795206B2 JP2022577490A JP2022577490A JP7795206B2 JP 7795206 B2 JP7795206 B2 JP 7795206B2 JP 2022577490 A JP2022577490 A JP 2022577490A JP 2022577490 A JP2022577490 A JP 2022577490A JP 7795206 B2 JP7795206 B2 JP 7795206B2
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
antibody fragment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022577490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531189A5 (cg-RX-API-DMAC7.html
JP2023531189A (ja
Inventor
ジェイ エム ショート
ガーハード フレイ
フウェイ ウェン チャング
ジン ワン
チャオ シン
Original Assignee
バイオアトラ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオアトラ インコーポレイテッド filed Critical バイオアトラ インコーポレイテッド
Publication of JP2023531189A publication Critical patent/JP2023531189A/ja
Publication of JP2023531189A5 publication Critical patent/JP2023531189A5/ja
Priority to JP2025247571A priority Critical patent/JP2026053430A/ja
Application granted granted Critical
Publication of JP7795206B2 publication Critical patent/JP7795206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022577490A 2020-06-18 2021-06-15 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用 Active JP7795206B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025247571A JP2026053430A (ja) 2020-06-18 2025-12-12 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040913P 2020-06-18 2020-06-18
US63/040,913 2020-06-18
PCT/US2021/037400 WO2021257542A1 (en) 2020-06-18 2021-06-15 Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025247571A Division JP2026053430A (ja) 2020-06-18 2025-12-12 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Publications (3)

Publication Number Publication Date
JP2023531189A JP2023531189A (ja) 2023-07-21
JP2023531189A5 JP2023531189A5 (cg-RX-API-DMAC7.html) 2024-06-18
JP7795206B2 true JP7795206B2 (ja) 2026-01-07

Family

ID=79268294

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022577490A Active JP7795206B2 (ja) 2020-06-18 2021-06-15 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用
JP2025247571A Pending JP2026053430A (ja) 2020-06-18 2025-12-12 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025247571A Pending JP2026053430A (ja) 2020-06-18 2025-12-12 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Country Status (11)

Country Link
US (1) US20230242662A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168452A4 (cg-RX-API-DMAC7.html)
JP (2) JP7795206B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230023800A (cg-RX-API-DMAC7.html)
CN (1) CN115702167A (cg-RX-API-DMAC7.html)
AU (1) AU2021292486A1 (cg-RX-API-DMAC7.html)
CA (1) CA3182384A1 (cg-RX-API-DMAC7.html)
IL (1) IL298902A (cg-RX-API-DMAC7.html)
MX (1) MX2022016197A (cg-RX-API-DMAC7.html)
TW (2) TWI906314B (cg-RX-API-DMAC7.html)
WO (1) WO2021257542A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544493A (ja) 2010-09-03 2013-12-19 ステム セントリックス, インコーポレイテッド 新規モジュレータ及びその使用法
JP2018534932A (ja) 2015-11-02 2018-11-29 バイオアトラ、エルエルシー 条件的活性型ポリペプチド
JP2019528323A (ja) 2016-08-31 2019-10-10 バイオアトラ、エルエルシー 条件的活性型ポリペプチド及びそれを生成する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP3191524A4 (en) * 2014-09-12 2018-05-30 The Regents of The University of California Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US11434301B2 (en) * 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
CN109535260B (zh) * 2018-11-22 2021-08-10 东南大学 一种靶向cd46的人源嵌合抗原受体及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544493A (ja) 2010-09-03 2013-12-19 ステム セントリックス, インコーポレイテッド 新規モジュレータ及びその使用法
JP2018534932A (ja) 2015-11-02 2018-11-29 バイオアトラ、エルエルシー 条件的活性型ポリペプチド
JP2019528323A (ja) 2016-08-31 2019-10-10 バイオアトラ、エルエルシー 条件的活性型ポリペプチド及びそれを生成する方法

Also Published As

Publication number Publication date
JP2026053430A (ja) 2026-03-25
CA3182384A1 (en) 2021-12-23
CN115702167A (zh) 2023-02-14
TWI906314B (zh) 2025-12-01
US20230242662A1 (en) 2023-08-03
WO2021257542A1 (en) 2021-12-23
IL298902A (en) 2023-02-01
TW202214696A (zh) 2022-04-16
TW202607039A (zh) 2026-02-16
EP4168452A4 (en) 2024-07-10
MX2022016197A (es) 2023-04-05
KR20230023800A (ko) 2023-02-17
AU2021292486A1 (en) 2023-02-09
JP2023531189A (ja) 2023-07-21
EP4168452A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
US20230235054A1 (en) Conditionally active anti-nectin-4 antibodies
US12427347B2 (en) Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof
US20250230237A1 (en) Humanized antibodies with increased stability
JP7856312B2 (ja) 条件的に活性な抗her2抗体、抗体断片、それらの免疫コンジュゲート、およびそれらの使用
TWI906314B (zh) 條件性活性抗cd46抗體、抗體片段、其免疫結合物及其用途
HK40087739A (en) Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof
HK40089117A (en) Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251212

R150 Certificate of patent or registration of utility model

Ref document number: 7795206

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150